摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

盆麦斯太罗 | 67-81-2

中文名称
盆麦斯太罗
中文别名
D-泛酸钠;戊甲夫醇
英文名称
Penmesterol
英文别名
(8R,9S,10R,13S,14S,17S)-3-cyclopentyloxy-10,13,17-trimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-ol
盆麦斯太罗化学式
CAS
67-81-2
化学式
C25H38O2
mdl
——
分子量
370.6
InChiKey
ZUBDXGHKAAMAAA-RFXJPFPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    162-168 °C(lit.)
  • 溶解度:
    H2O:≤0.5 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    27
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.84
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险类别码:
    R63,R45
  • 安全说明:
    S26

文献信息

  • Nitric Oxide Releasing Prodrugs of Therapeutic Agents
    申请人:SATYAM Apparao
    公开号:US20110263526A1
    公开(公告)日:2011-10-27
    The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.
    本发明涉及已知药物或治疗剂的一氧化氮释放前药,其在此处表示为式(I)的化合物,其中药物或治疗剂包含一个或多个功能基团,独立地选自羧酸基、羟基和巯基。该发明还涉及制备一氧化氮释放前药(式(I)的化合物)的方法,含有它们的药物组合物以及使用这些前药的方法。
  • Somatostatin antagonists and agonists
    申请人:——
    公开号:US20020091090A1
    公开(公告)日:2002-07-11
    Compounds according to the formula A-B-Z-W, wherein A is selected from (C 6 -C 10 )aryl-, or (C 1 -C 9 )heteroaryl-, which groups may be optionally substituted; B is selected from (a) O, NH, NR 10 , —(CH 2 ) k —O—, —(CH 2 ) k —N—, and —(CH 2 ) k —NR 10 —, where R 10 is (C 1 -C 6 )alkyl and where k is 1 to 6 in each case, or 1 where said group (i) through (iv) is optionally substituted by 1 to 4, preferably 1 to 2, groups selected from (C 1 -C 6 )alkyl, halo, and (C 1 -C 6 )alkyl optionally substituted by 1 to 3 halo atoms wherein one of carbon atoms C 1 , C 2 , C 3 and C 4 of said piperidine or piperazine group is optionally replaced by a carbonyl group; Z and W are as herein described; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammels.
    根据公式A-B-Z-W,其中 A选自(C6-C10)芳基或(C1-C9)杂环芳基,这些基团可以选择性地被取代; B选自 (a) O、NH、NR10、—(CH2)k—O—、—( )k—N—和—( )k—NR10—,其中R10为(C1-C6)烷基,k在每种情况下为1至6,或 1所述的该组(i)至(iv)可以选择性地被1至4个,优选1至2个,选自(C1-C6)烷基、卤素和(C1-C6)烷基,该烷基可以选择性地被1至3个卤原子取代,其中所述哌啶哌嗪基团的碳原子C1、C2、C3和C4中的一个可以选择性地被羰基取代; Z和W如本文所述;以及其药学上可接受的盐、溶剂化合物或合物;其制药组合物;以及用于促进哺乳动物分泌生长激素(GH)的方法。
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    申请人:——
    公开号:US20020091125A1
    公开(公告)日:2002-07-11
    Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′—(CH 2 ) n —, A′—(CH 2 ) n SO 2 —, and A′—(CH 2 ) n CO—, where n is 0 to 4; and A′ is selected from (a) (C 6 -C 10 )aryl-, or (b) (C 1 -C 9 )heteroaryl-; which groups may be optionally substituted; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammals.
    根据本文描述的公式A-Z-W,其中A是从以下组中选择的:A′—(CH2)n—,A′—( )nSO2—和A′—( )nCO—,其中n为0到4;A′是从(a) (C6-C10)芳基-,或(b) (C1-C9)杂环芳基-中选择的;这些基团可以选择性地被取代;以及其药学上可接受的盐、溶剂化合物或合物;以及其中的药物组合物;以及用于促进哺乳动物中生长激素(GH)分泌的方法。
  • Technology for the Preparation of Microparticles
    申请人:Malakhov Michael
    公开号:US20090098207A1
    公开(公告)日:2009-04-16
    Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触,并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
  • Pharmaceutical preparation comprising an active dispersed on a matrix
    申请人:——
    公开号:US20040058896A1
    公开(公告)日:2004-03-25
    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.
    本发明涉及制药技术领域,描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中,活性成分基本上均匀地分散在由脂肪醇甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B